9 results were returned
We were successful in defending our clients in a major Supplementary Protection Certificate (SPC) case.
International law firm Bird & Bird advises Mitsubishi Chemical Advanced Materials (MCAM), a leading global manufacturer of high-performance materials and a business division of Mitsubishi Chemical Corporation, Japan, on ...
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) – one of Bird & Bird’s key clients – is entitled to a preliminary injunction against ...
The English Court of Appeal has today handed down its decision in the dispute between pharmaceutical companies, Merck KGaA, Darmstadt, Germany, and US-based Merck Sharp & Dohme Corp (MSD) for breach of contract and ...
Almost two years ago, the Higher Regional Court Düsseldorf first iterated new liability criteria with respect to Second Medical Use Patents (cf. decision Östrogenblocker of May 5, 2017, docket no. I-2 W 6/17).
This decision follows the recent trend for the ECJ to give more straightforward interpretations of the SPC Regulation, providing certainty for users of the system.
Bird & Bird LLP has advised Vitruvian Partners LLP, a European private equity firm and investor in healthcare service provider doctari GmbH, on its acquisition of three companies.
We have advised Aphria Deutschland GmbH on its tender for the cultivation, processing and delivery of cannabis for medical purposes.
Bird & Bird is delighted to announce that we have received an excellent set of results in the 2018 edition of Legal 500: EMEA. As well as 34 top-tier rankings across our EMEA offices, we were recommended in a further ...